REG - Diaceutics PLC - Diaceutics PLC – Directorate Changes

DiaceuticsAnnouncement

21/09/2023 14:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230921:nRSU2604Na&default-theme=true

RNS Number : 2604N  Diaceutics PLC  21 September 2023

Diaceutics PLC - Directorate Changes

 

Graham Paterson appointed as an independent Non-Executive Director

 

Charles Hindson retiring as a Non-Executive Director

 

Belfast and London, 21 September 2023 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharmaceutical industry, today announces the appointment of
Graham Paterson as an independent Non-Executive Director of Diaceutics PLC
effective 1 October 2023. The Company also announces the retirement of Charles
Hindson as a Non-Executive Director of Diaceutics PLC also effective 1 October
2023.

 

Graham Paterson is a highly experienced business leader and Non-Executive
Director. He is currently a Non-Executive Director of Invesco Perpetual UK
Smaller Companies Investment Trust plc, Baillie Gifford US Growth Trust plc
and Chairman of Mobeus Income and Growth 4 VCT plc. He has held senior
executive roles in a number of companies including TopQ Software Ltd and SL
Capital Partners.

 

Graham Paterson is a Chartered Accountant and a member of the Institute of
Chartered Accountants of Scotland and holds an Honours degree in Economics
and Management from the University of St. Andrews. On appointment, Graham
Paterson will become Chair of the Audit and Remuneration Committees of
Diaceutics PLC.

 

Deborah Davis, Diaceutics' Non-Executive Chair, commented: "I would like to
thank Charles for his hard work, dedication and much valued counsel during the
past four years and wish him well in his future endeavours.

 

I warmly welcome Graham to the board of Diaceutics, his extensive leadership
and board experience will contribute significantly to our work and support our
growth as we become the primary commercialisation partner for pharma and
biotech companies launching precision medicines."

 

Information required to be disclosed pursuant to Schedule Two, paragraph (g)
of the AIM Rules for Companies:

The following information is disclosed in relation to Graham Douglas
Paterson, aged 52:

 Current Directorships                                         Past Directorships (previous 5 years)
 Baillie Gifford US Growth Trust Plc                           The IDco Ltd

 Invesco Perpetual UK Smaller Companies Investment Trust Plc   Octopus VCT 4 Plc

 Mobeus Income and Growth 4 VCT Plc                            Berry Starquest Limited

 Datactics Ltd

 Substantive Research Ltd

 The Wemyss Development Company Ltd

 GDP 1 Ltd

Graham Paterson does not hold any ordinary shares or share options in the
Company.

Save for the information disclosed above, there is no other information to be
disclosed under Schedule 2(g) of the AIM Rules.

 

Enquiries:

 Diaceutics PLC                                        Tel: +44 (0)28 9040 6500
 Peter Keeling, Chief Executive Officer               investorrelations@diaceutics.com

 Ryan Keeling, Chief Innovation Officer

 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland

 Kate Hanshaw

 Alma PR                                              Tel: +44 (0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Matthew Young
 Kinvara Verdon

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialization solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The Diagnostic
Network®.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOALBMJTMTJTBJJ